Cardiovascular Imaging in Pediatric Myocarditis

A Cohort Study: to Assess the Value of Cardiovascular Imaging in Pediatric Myocarditis

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06652399

Enrollment

100

Registered

2024-10-22

Start date

2023-11-01

Completion date

2033-04-01

Last updated

2024-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocarditis

Brief summary

This study aims to utilize cardiac magnetic resonance (CMR) to assist in the clinical diagnosis, conduct consecutive assessments for myocardial tissue in pediatrics with myocarditis, and explore effective predictive factors for adverse outcomes in pediatric myocarditis. Participants will undergo baseline collection, laboratory tests, echocardiography, and CMR. All the consecutive data will be used to analyze the association with the diagnosis and prognosis of pediatric myocarditis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 18 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients diagnosed or suspected pediatric myocarditis based on Diagnostic Recommendation for Myocarditis in Children (version 2018). * Age between 1 to 18 years old.

Exclusion criteria

* Previous history of cardiovascular disease ( e.g. congenital heart disease, cardiomyopathy, rheumatic heart disease, valvular disease ). * MRI examination contraindications ; * Gadolinium contrast agent contraindications ; * CT examination contraindications ; * Comparison of iodine content.

Design outcomes

Primary

Measure	Time frame	Description
Adverse cardiovascular events	10 years after the onset	including all-cause death, orthotopic heart transplantation(HTx), malignant arrhythmia, readmission due to heart failure, progression to DCM.

Secondary

Measure	Time frame	Description
Secondary cardiovascular adverse events	10 years after the onset	including mild reduction of cardiac function, persistent mild AVB and other arrhythmias, left chest tightness, palpitations and other clinical symptoms.

Countries

China

Outcome results